The Alzheimer’s Thermometer Fallacy

Treating Alzheimer’s disease by targeting amyloid is like treating a fever by lowering the thermometer reading.

This analogy starkly reveals the fundamental misdirection that has dominated Alzheimer’s disease (AD) research and drug development for over 30 years. The field’s fixation on amyloid-beta (Aβ) plaques as the root cause of AD has led to hundreds of clinical trials, billions of dollars spent, and numerous high-profile failures — yet no breakthrough therapy has meaningfully slowed or reversed cognitive decline in patients.

The Rise and Entrenchment of the Amyloid Hypothesis

The amyloid cascade hypothesis took hold in the early 1990s following landmark genetic discoveries linking familial AD to mutations in APP and presenilin genes (Hardy & Higgins, 1992). This framed Aβ accumulation as the initiating event in AD pathology, setting the field on a narrow course toward amyloid-targeting therapies.

Pharmaceutical companies such as Pfizer, Eli Lilly, Biogen, and Roche invested heavily in antibodies and small molecules designed to reduce amyloid plaques. The U.S. National Institute on Aging (NIA) and Alzheimer’s Association also prioritized amyloid-centric research funding, further solidifying this focus across academia.

Industry Failures: A History of High-Profile Trial Collapses

Despite extensive investment, exceeding $20 billion globally (Cummings et al., 2016; Mullane & Williams, 2020), the results from major clinical trials targeting amyloid have been consistently disappointing:

• Bapineuzumab (Pfizer/Janssen/Elan): This antibody aimed to clear amyloid plaques but failed to demonstrate clinical benefit in Phase 3 trials (NCT00575055) published in 2014. The trial enrolled over 2,000 patients and ultimately led to program termination after billions spent (Salloway et al., 2014).
• Solanezumab (Eli Lilly): The EXPEDITION trials (NCT00905372, NCT00904683) failed to meet primary cognitive endpoints despite amyloid reduction. Marginal effects seen in mild AD were insufficient for approval. Lilly invested over $1.6 billion in development (Doody et al., 2014; Mullane & Williams, 2020).
• Aducanumab (Biogen/Eisai): After two Phase 3 trials (EMERGE NCT02484547 and ENGAGE NCT02477800) yielded conflicting results, Biogen obtained accelerated FDA approval in 2021 based mainly on amyloid PET reductions and post-hoc cognitive analyses (Biogen, 2021). This sparked resignations from FDA advisory panelists and widespread controversy over clinical benefit and safety risks, including amyloid-related imaging abnormalities (ARIA) seen in ~35% of treated patients (Knopman et al., 2021). The treatment costs approximately $28,000 per year, raising concerns about value.
• Lecanemab (Eisai/Biogen): The 2023 Clarity AD Phase 3 trial (NCT03887455) demonstrated a 27% slowing in cognitive decline over 18 months, with ARIA incidence under 10% (Swanson et al., 2023). While statistically significant, the clinical relevance remains debated, with some experts questioning the real-world impact given modest effect size and treatment burden (Cummings et al., 2023). Annual cost is approximately $26,000.
• Donanemab (Eli Lilly): Phase 2 and 3 trials (NCT03367403) showed amyloid clearance and modest cognitive benefits, but safety concerns and uncertain clinical relevance persist. Regulatory approval is pending (Mintun et al., 2021).

This pattern is clear: achieving amyloid clearance has not reliably translated into meaningful improvements in cognition or patient quality of life.

Academic and Regulatory Entrenchment

Academic institutions, funding agencies, and regulatory bodies have reinforced the amyloid hypothesis, creating a powerful inertia resistant to challenge:

• The Dominantly Inherited Alzheimer Network (DIAN), funded by NIH, initially embraced amyloid as causal in familial AD, but recent data highlight complex, earlier pathophysiological changes beyond amyloid deposition (Bateman et al., 2012; Gordon et al., 2018).
• Prestigious journals such as Nature, Science, and Neuron have often prioritized amyloid-focused research, influencing scientific careers and funding.
• The FDA’s accelerated approval of aducanumab was widely criticized for basing approval on surrogate endpoints (amyloid PET reduction) rather than robust cognitive benefits. Experts like Dr. Aaron Kesselheim called the approval “a serious setback for Alzheimer’s research” (STAT News, 2021).

Why Amyloid Is the Thermometer, Not the Infection

Amyloid plaques are late-stage manifestations, likely reflecting downstream effects of earlier cellular and molecular dysfunction:

• Amyloid may serve a compensatory or protective role, possibly as an antimicrobial peptide or part of innate immunity (Soscia et al., 2010).
• Other pathological proteins — tau, α-synuclein, and TDP-43 — are also byproducts of complex, dysregulated systems rather than primary causes.
• Transcriptomic and systems biology studies reveal early neuronal and glial dysfunction well before plaque formation, underscoring the need to target upstream processes (Mathys et al., 2019; De Strooper & Karran, 2016).

No matter how effectively amyloid is cleared, the underlying neurodegenerative cascade continues unabated, driving cognitive decline.

The Ethical and Economic Cost of Biomarker Theater

The relentless pursuit of amyloid clearance has created a “biomarker theater” that misleads patients, clinicians, and policymakers:

• Patients face invasive, costly treatments that carry significant risks, including ARIA and cerebral edema, with only marginal benefit.
• Healthcare systems incur enormous financial burdens — e.g., annual treatment costs exceeding $25,000 per patient for marginal gains.
• Scientific resources are concentrated on incremental improvements targeting amyloid, delaying progress on causal biology and novel therapeutic avenues.

The sunk cost fallacy is strong: vested interests — scientists, pharmaceutical companies, and regulators — defend amyloid targeting to protect institutional prestige, career investments, and financial stakes.

Realigning Alzheimer’s Research Toward Causal Biology

True progress demands a paradigm shift:

• Funding agencies such as NIH and private foundations must prioritize research on early transcriptomic dysfunction, neuroinflammation, mitochondrial integrity, and metabolic pathways.
• Multi-omics and systems biology platforms (e.g., Bioada’s proprietary platform, Genomarker) can identify upstream drivers of neurodegeneration before irreversible pathology ensues.
• Therapeutics should target cellular resilience, immune modulation, and metabolic support, rather than just downstream protein aggregates.

Time to Treat the Disease, Not Its Debris

Alzheimer’s disease is a complex, multifactorial disorder requiring approaches that go beyond amyloid clearance. Continuing to engineer better antibodies or delivery systems for a fundamentally irrelevant target only accelerates failure.